Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient
An object of the present invention is to find a new pharmaceutical application of a prostaglandin F2α derivative. It was found that the prostaglandin F2α derivative inhibits glutamate-induced retinal neuronal cell death in a concentration-dependent manner in rat fetal retinal neuronal cells, in other words, the prostaglandin F2α derivative acts directly on the retinal neuronal cells and exhibits a protective effect. Accordingly, the prostaglandin F2α derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage.
1 . A protective agent for a retinal neuronal cell comprising a prostaglandin F2α derivative as an active ingredient.
2 . The protective agent for a retinal neuronal cell according to claim 1 , wherein the prostaglandin F2α derivative is a fluorine-containing prostaglandin F2α derivative.
3 . The protective agent for a retinal neuronal cell according to claim 2 , wherein the fluorine-containing prostaglandin F2α derivative is a 15,15-difluoroprostaglandin F2α derivative.
4 . The protective agent for a retinal neuronal cell according to claim 3 , wherein the 15,15-difluoroprostaglandin F2α derivative is a compound represented by the following general formula (I) or a salt thereof:
wherein R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent.
5 . The protective agent for a retinal neuronal cell according to claim 4 , wherein in the general formula (I), R represents a carboxy group or a salt group thereof or an alkoxycarbonyl group.
6 . The protective agent for a retinal neuronal cell according to claim 2 , wherein the fluorine-containing prostaglandin F2α derivative is a 15-monofluoroprostaglandin F2α derivative.
7 . The protective agent for a retinal neuronal cell according to claim 1 , wherein the retinal neuronal cell is a photoreceptor cell, a bipolar cell, an optic ganglion cell, a horizontal cell or an amacrine cell.
8 . The protective agent for a retinal neuronal cell according to claim 1 , which is used for the prevention or treatment of an eye disease.
9 . A method of protecting a retinal neuronal cell comprising administering an effective amount of a prostaglandin F2α derivative to a patient.
10 . The protection method according to claim 9 , wherein the prostaglandin F2α derivative is a fluorine-containing prostaglandin F2α derivative.
11 . The protection method according to claim 10 , wherein the fluorine-containing prostaglandin F2α derivative is a 15,15-difluoroprostaglandin F2α derivative.
12 . The protection method according to claim 11 , wherein the 15,15-difluoroprostaglandin F2α derivative is a compound represented by the following general formula (I) or a salt thereof:
wherein R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent.
13 . The protection method according to claim 12 , wherein in the general formula (I), R represents a carboxy group or a salt group thereof or an alkoxycarbonyl group.
14 . The protection method according to claim 10 , wherein the fluorine-containing prostaglandin F2α derivative is a 15-monofluoroprostaglandin F2α derivative.
15 . The protection method according to claim 13 , wherein the retinal neuronal cell is a photoreceptor cell, a bipolar cell, an optic ganglion cell, a horizontal cell or an amacrine cell.
16 . A method of preventing or treating an eye disease associated with retinal neuronal cell damage comprising administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient.
17 . The prevention or treatment method according to claim 16 , wherein the prostaglandin F2α derivative is a fluorine-containing prostaglandin F2α derivative.
18 . The prevention or treatment method according to claim 17 , wherein the fluorine-containing prostaglandin F2α derivative is a 15,15-difluoroprostaglandin F2α derivative.
19 . The prevention or treatment method according to claim 18 , wherein the 15,15-difluoroprostaglandin F2α derivative is a compound represented by the following general formula (I) or a salt thereof:
wherein R represents a hydroxyalkyl group, a formyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group, and when R is an aryloxycarbonyl group or an arylaminocarbonyl group, the aryl moiety thereof may have a substituent.
20 . The prevention or treatment method according to claim 19 , wherein in the general formula (I), R represents a carboxy group or a salt group thereof or an alkoxycarbonyl group.
21 . The prevention or treatment method according to claim 17 , wherein the fluorine-containing prostaglandin F2α derivative is a 15-monofluoroprostaglandin F2α derivative.
22 . The prevention or treatment method according to claim 16 , wherein the retinal neuronal cell is a photoreceptor cell, a bipolar cell, an optic ganglion cell, a horizontal cell or an amacrine cell.
23 - 30 . (canceled)